Bone alkaline phosphatase isoenzyme and carboxy-terminal propeptide of type-I procollagen in healthy Chinese girls and boys.
Conventional bone formation markers such as osteocalcin (1) have been shown to correlate with serum concentrations of insulin-like growth factor-I and testosterone in children and adolescents. In pathological conditions, osteocalcin (2-4) is lower in growth hormone-deficient children and increases with replacement therapy. Osteocalcin, however, is labile and possesses problems in sample processing and storage (15). Recently, two other bone formation markers in serum, bone alkaline phosphatase isoenzyme (BAP) (16) and the carboxy-terminal propeptide of type-I procollagen (PICP) (17), were shown to be sensitive and specific markers of bone formation. BAP has been shown to be lower in children with growth hormone deficiency (5). When these children were treated with growth hormone, BAP showed a substantial increase (5). Both PICP and BAP were also used to monitor the response to growth-promoting agents in short apparently healthy children (6). On the other hand, in children with precocious puberty treated with gonadotropin-releasing hormone agonists, PICP decreased, suggesting a favorable retarding effect on skeletal growth (7). PICP was reported to be lower in children treated with glucocorticoid for asthma (8) or inflammatory bowel disease (9). The serum concentration correlated with the growth velocities in children and adolescents having inflammatory bowel disease with or without corticosteroid therapy (9). These two markers are chemically much more stable than osteocalcin; therefore, their measured concentrations should be less sensitive to processing and storage conditions. The aim of this study was to investigate the age-related changes in serum concentrations of BAP and PICP in healthy Taiwanese girls and boys <18 years of age.
We collected fasting morning serum samples from 110 girls and 120 boys from the urban Taipei area in 1997. All of them gave blood for the purpose of hepatitis screening and were found to have normal liver, kidney, and thyroid function. None of them was receiving any medication or had diseases that could affect bone metabolism. After venipuncture, serum samples were aliquoted and stored at -70[degrees]C until analysis. The procedures were in accordance with the revised Helsinki declaration in 1983. Serum BAP was measured with immunocatalytic kits (Metra Biosystem). The interassay imprecision (CV) was 8% and the interassay CV was 11% at 25 U/L in our laboratory. Serum PICP was measured with radioimmunoassay kits (Orion Diagnostic). The interassay CV was 7% and the interassay CV was 9% at 285 [micro]g/L. All of the samples showed concentrations well above the detection limits of these assays.
The values of BAP and PICP of the different age groups are shown in Table 1. Both BAP and PICP showed sigmoid regression curves with increasing age (Fig. 1). Both markers showed mean values approximately fourfold higher than the upper reference limit for adults in the first 3 years of life in both genders. The PICP then was substantially lower after 3 years of age in both girls and boys until puberty. Prepubertal PICP was one- to twofold higher than the upper reference limit for adults. During puberty, PICP increased again to a mean of 250 [micro]g/L, approximately twofold higher than the upper limit of adults in each gender. After puberty, both girls (ages, 13-18 years) and boys (ages, 15-18 years) showed mean PICP concentrations at approximately the upper reference limit for adults. In contrast to the substantial decrease in PICP, BAP showed sustained high values in prepubertal girls and boys, a phenomenon similar to that of osteocalcin (13, 14). However, unlike the lack of higher osteocalcin in the first few years of life (13, 14), BAP was higher during the first 3 years of life than the prepubertal values during the next 5 years. After puberty, BAP showed a gradual decrease in girls and boys. In general, girls showed decreased postpubertal values of both markers 2 years earlier than boys, reflecting the earlier completion of puberty in girls. The correlation between PICP and BAP was significant in boys (n = 120; r = 0.261; P = 0.004), in girls (n = 110; r = 0.426; P = 0.0001), and in boys and girls together (n = 230; x = 0.306; P = 0.0001).
[FIGURE 1 OMITTED]
Although various bone markers have been used extensively in physiologic and clinical research in adults, much less information is available in children. Metabolic bone disorders in childhood are caused mainly by defects in osteoblastic functions, which emphasizes the important role of bone formation markers in pediatrics. The two markers examined in this study are stable, suitable for long-term storage, and showed little overlap between the adult values and the childhood/adolescent values. Unlike osteocalcin, they clearly showed higher concentrations in infancy, when the rate of growth was fastest. Both appear to be good tools for clinical and physiologic research.
(1.) Johansen JS, Giwerman A, Hartwell D. Thoger Nielsen C, Price PA, Christiansen C, et al. Serum bone Gla-protein as a marker of bone growth in children and adolescents: correlation with age, height, serum insulin-like growth factor 1, and serum testosterone. J Clin Endocrinol Metab 1988;67: 273-8.
(2.) Delmas PD, Chatelain P, Malaval L, Bonne G. Serum bone Gla-protein in growth hormone deficient children. J Bone Miner Res 1986;4:333-8.
(3.) Nielsen HK, Jorgensen JOL, Brixen K, Christiansen JS. Serum osteocalcin and bone isoenryme alkaline phosphatase in growth hormone-deficient patients: dose-response studies with biosynthetic human GH. Calcif Tissue Int 1991;48:82-7.
(4.) Stamoyannou L, Karachaliou F, Giourelie E, Voskaki E, Mengreli C, Barsocas CS. Effect of growth hormone therapy on bone metabolism of growth hormone deficient children. Eur J Pediatr 1997;156:592-6.
(5.) Tobiume H, Kanazaki S, Hida S, Ono T, Moriwake T, Yamanochi S, et al. Serum bone alkaline phosphatase isoenryme levels in normal children and children with growth hormone deficiency: potential marker for bone formation and response to GH therapy. J Clin Endocrinol Metab 1997;82: 2056-61.
(6.) Crofton PM, Stirling HF, Schonau E, Kelnar CJ. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatment in short normal children. Clin Endocrinol 1996; 44:385-94.
(7.) Boot AM, De Muinck Keizer-Schrama S, Pols HA, Krenning EP, Drop SL. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J Clin Endocrinol Metab 1998;41:1560-6.
(8.) Birkebaek NH, Esberg G, Andersen K, Wolthers 0, Hassager C. Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate. Arch Dis Child 1995;73:524-7.
(9.) Hyamas JS, Treem WR, Carey DE, Wyzga N, Eddy E, Goldberg D, Moore RE. Comparison of collagen propeptide as growth markers in children with inflammatory bowel disease. Gastroenterology 1991;100:971-5.
(10.) Tommasi M, Baccitottini L, Benucci A, Brocchi A, Passeri A, Saracini A, et al. Serum biochemical markers of bone turnover in healthy infants. Int J Biol Markers 1996;11:159-64.
(11). Crofton PM, Wade JC, Taylor MRH, Holland CV. Serum concentrations of carboxy-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxy-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren. Clin Chem 1997; 43:1577-81.
(12.) Weaver CM, Peacock M, Martin BR, Plawecki KL, McCabe GP. Calcium retention estimated from indicators of skeletal status in adolescent girls and young women. Am J Clin Nutr 1996;64:67-70.
(13.) Cioffi M, Molinari AM, Gazzerro P. Di Finizio B, Frata M, Deufemia A, Puca GA. Serum osteocalcin in 1634 healthy children. Clin Chem 1997;43: 543-5.
(14.) Lo S-F, Huang J-L, Chem L-C, Yeh K-W, Yang D-C, Hsieh K-H. Serum osteocalcin levels of normal children in Taiwan. Acta Paediatr Sin 1997;38: 443-7.
(15.) Banfi G, Daverio R. In vitro stability of osteocalcin. Clin Chem 1994;40: 883-4.
(16.) Gomez B Jr, Ardakani S, Ja T, Jenkins D, Cereli MJ, Daniloff GY, Gung VT. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995;41:1560-6.
(17.) Parfitt AM, Simon LS, Villaneuva AR, Krane SM. Procollagen type I carboxyterminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2:427-36.
(18.) Tsai K-S, Pan W-H, Hsu SH-J, Cheng W-C, Chen C-K, Chieng P-U, et al. Sexual difference in bone markers and bone mineral density of normal Chinese. Calcif Tissue Int 1996;59:454-60.
Keh-Sung Tsai,  Men-Hwang Jang,  Sandy Huey-Jen Hsu,  Wern-Cherng Cheng,  and Mei-Hwei Chang  (Departments of  Laboratory Medicine and  Pediatrics, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China;  Department of Laboratory Medicine, Taipei City Psychiatric Center, Taipei, Taiwan, Republic of China; * address correspondence to this author at: Department of Laboratory Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan, Republic of China; fax 8862-23224263, e-mail firstname.lastname@example.org)
Table 1. Mean values ([+ or -] SD) of PICP and BAP in different age groups of both genders. Early childhood Prepubertal Girls Boys Girls Age, years 0-2 0-2 3-8 n 20 20 43 PICP, 557 [+ or -] 260 784 [+ or -] 329 216 [+ or -] 93 [micro]g/L Range 230-1104 211-1310 155-558 BAP, U/L 122 [+ or -] 19 104 [+ or -] 21 106 [+ or -] 16 Range 81-142 62-132 70-139 Prepubertal Pubertal Boys Girls Boys Age, years 3-9 9-12 10-14 n 50 37 41 PICP, 223 [+ or -] 118 243 [+ or -] 65 268 [+ or -] 113 [micro]g/L Range 147-930 122-373 123-618 BAP, U/L 94 [+ or -] 17 112.4 [+ or -] 16 114 [+ or -] 21 Range 63-135 66-137 58-140 Postpubertal Girls Boys Age, years 13-17 15-18 n 10 9 PICP, 129 [+ or -] 29 155 [+ or -] 20 [micro]g/L Range 74-167 127-189 BAP, U/L 39 [+ or -] 23 59 [+ or -] 19 Range 8-82 30-89 Young adult (a) Women Men Age, years 20-50 20-50 n 118 68 PICP, 82 [+ or -] 22 116 [+ or -] 11 [micro]g/L Range 37-133 77-163 BAP, U/L 17 [+ or -] 6 20 [+ or -] 8 Range 6-34 10-45 (a) Values for young adults were from Tsai et al. (18).
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Technical Briefs|
|Author:||Tsai, Keh-Sung; Jang, Men-Hwang; Hsu, Sandy Huey-Jen; Cheng, Wern-Cherng; Chang, Mei-Hwei|
|Date:||Jan 1, 1999|
|Previous Article:||Simple method for improving the precision of electrolyte measurements in vitreous humor.|
|Next Article:||Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results.|